Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma

Diffuse Large B-Cell Lymphoma

(2021) Laurie H. Sehn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis

(2020) Sirpa Leppä et al.   Blood Advances

Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma

(2019) Luc-Matthieu Fornecker et al.   Scientific Reports

Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients

(2018) Susanne Bram Ednersson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Structure and Expression of Different Serum Amyloid A (SAA) Variants and their Concentration-Dependent Functions During Host Insults

(2016) Mieke Buck et al.   CURRENT MEDICINAL CHEMISTRY

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

(2014) D. W. Scott et al.   BLOOD

Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study

(2012) H. Holte et al.   ANNALS OF ONCOLOGY

Non-Hodgkin lymphoma

(2012) Kate R Shankland et al.   LANCET

Rearrangement ofMYCIs Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab

(2010) Sharon Barrans et al.   JOURNAL OF CLINICAL ONCOLOGY

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY